Showing results (281-290 of 311) with videos related to

Sort By:
Pageof 32
Journal of Medicinal Chemistry|October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitorsMichael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Journal of Medicinal Chemistry|February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.
Chemical Science|September 12, 2022
Establishing the selective phospholipid membrane coordination, permeation and lysis properties for a series of 'druggable' supramolecular self-associating antimicrobial amphiphilesJessica E Boles, Charlotte Bennett, Jennifer Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid TumorsRobert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, et al.
Cell Host & Microbe|February 15, 2019
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and ColitisLasha Gogokhia, Kate Buhrke, Rickesha Bell, et al.
Bioscience|March 10, 2023
How Social Considerations Improve the Equity and Effectiveness of Ecosystem RestorationSara Löfqvist, Fritz Kleinschroth, Adia Bey, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
The Biochemical Journal|October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathwayJill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Pageof 32